Mylan Plans Half-Priced Generic Version of EpiPen

The video discusses Mylan's strategy to release a generic version of the EpiPen in response to criticism over high prices. It explores the dynamics of the pharmaceutical market, including competition and pricing strategies. The video also addresses congressional scrutiny and the legislative efforts that allowed Mylan to increase EpiPen prices steadily over time.

What strategies did Mylan employ to maintain control over the EpiPen market?

How did Mylan's pricing strategy differ from that of other pharmaceutical companies facing generic competition?

What role did Congress play in the scrutiny of Mylan's pricing practices?

In what ways did Mylan's actions respond to criticism regarding the pricing of the EpiPen?

What factors contributed to the significant price increase of the EpiPen from 2007 to the present?